Using skin models to assess the effects of a protection cream on skin barrier function

Skin Pharmacology and Physiology

Volumn 17, Issue 4, 2004, Pages 167-175

  Zur Muhlen A ^a,b   Klotza, A ^a   Weimans, S ^b   Veeger, M ^a   Thorner B ^a   Diener, B ^b   Hermann, M ^b  

^a Lab for Toxicology and Ecology   (Germany)

^b EVONIK INDUSTRIES AG   (Germany)

Author keywords

In vitro testing; In vivo testing; Skin barrier function; Skin lipids; Skin protection; Three dimensional skin models

Indexed keywords

COSMETIC; DODECYL SULFATE SODIUM; LIPID EMULSION; SKIN LIPID; SKIN PROTECTIVE AGENT;

ADULT; ARTICLE; CELL DAMAGE; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EMULSION; FEMALE; HUMAN; IN VITRO STUDY; MALE; MODEL; NORMAL HUMAN; PRIORITY JOURNAL; SKIN PROTECTION;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; CERAMIDES; DINOPROSTONE; EMULSIONS; FEMALE; HUMANS; INTERLEUKIN-1; IRRITANTS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; OINTMENTS; PETROLATUM; PROTECTIVE AGENTS; REPRODUCIBILITY OF RESULTS; SKIN; SKIN ABSORPTION; SKIN IRRITANCY TESTS; SODIUM DODECYL SULFATE;

EID: 3242814719     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078819     Document Type: Article

References (39)

1. Diepgen TL, Coenraads PJ: The epidemiology of occupational contact dermatitis. Int Arch Occup Environ Health 1999;73:496-506.
2. Kucharekova M, Schalkwijk J, van de Kerkhof PC, van de Valk PG: Effect of a lipid-rich emollient containing ceramide 3 in experimentally induced skin barrier dysfunction. Contact Dermatitis 2002;46:331-338.
3. Kresken J, Klotz A: Occupational skin protection products - A review. Int Arch Occup Environ Health 2003;76:355-358.
4. Zhai H, Maibach H: Efficacy of barrier creams; in Maibach HI, Elsner P (eds): Cosmeceuticals. New York, Dekker, 2000, pp 249-264.
5. Schnetz E, Diepgen TL, Elsner P, Frosch PJ, Klotz AJ, Kresken J, Kuss O, Merk H, Schwanitz HJ, Wigger-Alberti W, Fartasch M: Multicentre study for the development of an in vivo model to evaluate the influence of topical formulations on irritation. Contact Dermatitis 2000;42:336-343.
6. Roguet R: The use of standardized human skin models for cutaneous pharamtoxicology studies. Skin Pharmacol Appl Skin Physiol 2002; 15:1-3.
7. Ponec M, Boelsma E, Gibbs S, Mommaas M: Characterization of reconstructed skin models. Skin Pharmacol Appl Skin Physiol 2002;15:4-17.
8. Ponec M, Weerheim A, Mulder A, Gooris G, Bouwstra J, Mommaas M: The formation of competent barrier lipids in the reconstructed epidermis requires the prevalence of vitamin C. J Invest Dermatol 1997;109:348-355.
9. Ponec M, Boelsma E, Weerheim A: Covalent bound lipids in reconstructed human epithelia. Acta Derm Venereol 2000;80:89-93.
10. Bouwstra J, Gooris G, Weerheim A, Kempenaar J, Ponec M: Characterisation of stratum corneum structure in reconstructed epidermis by X ray diffraction. J Lipid Res 1995;36:496-504.
11. Ponec M, Gibbs S, Pilgram G, Boelsma E, Koerten H, Bouwstra J, Mommaas M: Barrier function in reconstructed epidermis and its resemblance to native human skin. Skin Pharmacol Appl Skin Physiol 2001;14:63-71.
12. Pinnagoda J, Tupker RA, Agner T, Serup J: Guidelines for transepidermal water loss (TEWL) measurements. Contact Dermatitis 1990;22:164-178.
13. Ponec M, Weerheim A: Retinoids and lipids changes in keratinocytes. Methods Enzymol 1990;190:30-41.
14. Greif C, Wigger-Alberti W, Elsner P: Emollients and barrier creams in the prevention of hand eczema; in Menné T, Maibach HI (eds): Hand Eczema. Boca Raton, CRC Press, 2000, pp 323-331.
15. Ramsing DW, Agner T: Preventive and therapeutic effects of a moisturizer. An experimental study of human skin. Acta Derm Venereol 1997;77:335-337.
16. De Paepe K, Hachem JP, Vanpee E, Goossens A, Germaux M-A, Lachapelle JM, Lambert J, Matthieu L, Roseeuw D, Suys E, Hecke EV, Rogiers V: Beneficial effects of a skin tolerancetested moisturizing cream on the barrier function in experimentally-elicited irritant and allergic contact dermatitis. Contact Dermatitis 2001;44:337-343.
17. Faller C, Bracher M: Reconstructed skin kits: Reproducability of cutaneous irritancy testing. Skin Pharmacol Appl Skin Physiol 2002;15: 74-91.
18. Fletcher ST, Baker VA, Fentem JH, Basketter DA, Kelsell DP: Gene expression analysis of EpiDerm following exposure to SLS using cDNA microarrays. Toxicol In Vitro 2001;15: 393-398.
19. Feingold KR, Elias PM: The environmental interface: Regulation of permeability barrier homeostasis; in Loden M, Maibach HI (eds): Dry Skin and Moisturizers. Boca Raton, CRC Press, 2000, pp 45-58.
20. Bouwstra JA, Gooris GS, Dubbelaar FER, Weerheim AM, Ijzerman AP, Ponec M: Role of ceramide 1 in the molecular organization of the stratum corneum lipids. J Lipid Res 1998;39: 186-196.
21. Perkins MA, Osborne R, Rana FR, Ghassemi A, Robinson MK: Comparison of in vitro and in vivo human skin responses to consumer products and ingredients with a range of irritancy potential. Toxicol Sci 1999;48:218-229.
22. Roguet R: Use of skin cell cultures for in vitro assessment of corrosion and cutaneous irritancy. Cell Biol Toxicol 1999;15:63-75.
23. Cohen C: Measurement of inflammatory mediators produced by human keratinocytes in vitro: A predictive assessment of cutaneous irritation. Toxicol In Vitro 1991;5:407-410.
24. Bernhofer LP, Barkovic S, Appa Y, Martin KM: IL-1 alpha and IL-1 ra secretion from epidermal equivalents and the prediction of the irritation of mild soap and surfactant-based consumer products. Toxicol In Vitro 1999;13: 231-239.
25. Bernhofer LP, Seiberg M, Martin KM: The influence of the response of skin equivalent systems to topically applied consumer products by epithelial-mesenchymal interactions. Toxicol In Vitro 1999;13:219-229.
26. Gay R, Swidderek M, Nelson D, Ernesti A: The living skin equivalent as a model in vitro for ranking the toxic potential of dermal irritants. Toxicol In Vitro 1992;6:303-315.
27. Müller-Decker K, Heinzelmann T, Fürstenberger, Kecskes A, Lehmann W-D, Marks F: Arachidonic acid metabolism in primary irritant dermatitis produced by patch testing of human skin with surfactants. Toxicol Appl Pharmacol 1998;153:59-67.
28. Bloom E, Sznitowska M, Polansky J, Ma D, Maibach HI: Increased proliferation of skin cells by sublethal doses of sodium lauryl sulfate. Dermatology 1994;188:263-268.
29. Elias PM, Feingold KR: Coordinate regulation of epidermal differentation and barrier homeostasis. Skin Pharmacol Appl Skin Physiol 2001; 14:28-34.
30. Elias PM, Ansel JC, Woods LC, Feingold KR: Signalling networks in barrier homeostasis: The mystery widens. Arch Dermatol 1996;132: 1505-1506.
31. Elias PM, Woods LC, Feingold KR: Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermat 1999;10:119-126.
32. Fartasch M, Schnetz E, Diepgen TL: Characterization of detergent-induced barrier alterations - Effect of barrier cream on irritation. J Investig Dermatol Symp Proc 1998;3:121-127.
33. Fulmer AW, Kramer GJ: Stratum corneum lipid abnormalities in surfactant-induced dry scaly skin. Soc Invest Dermatol 1986;86:598-602.
34. Fluhr JW, Elias PM: Stratum corneum pH: Formation and function of the 'acid mantle'. Exog Dermatol 2002;1:163-175.
35. Fluhr JW, Kao J, Jain M, Ahn SK, Feingold KR, Elias PM: Generation of free fatty acids from phospholipids regulates stratum corneum acidification and integrity. Soc Invest Dermatol 2001;117:44-51.
36. Geilen CC, Barz S, Bektas M: Sphingolipid signaling in epidermal homeostasis. Skin Pharmacol Appl Skin Physiol 2001;14:261-271.
37. Coderch L, Pera Md, Fonollosa J, Maza Adl, Parra JL: Efficacy of stratum corneum lipid supplementation on human skin. Contact Dermatitis 2002;47:139-146.
38. Zellmer S: Hautlipide, Vesikel aus Hautlipiden und ceramidhaltige Liposomen. SÖFW 2000; 126:37-40.
39. Klotz A, Zur Mühlen A, Röcher W, Kirchhof R, Veeger M: Neue Wirkprinzipien für Hautschutzmittel. Die BG 2002:460-463.